Search Results
Search for other papers by Krystallenia I Alexandraki in
Google Scholar
PubMed
Search for other papers by Gregory A Kaltsas in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by Eleftherios Chatzellis in
Google Scholar
PubMed
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
Introduction Neuroendocrine neoplasms (NENs), previously named ‘carcinoid’ tumours, most frequently occur in the gastrointestinal (GI) tract (54.5%) and have been an area of ongoing interest in the field of many different disciplines including
Search for other papers by Günter Klöppel in
Google Scholar
PubMed
Introduction Endocrine neoplasms can be divided according to the chemical nature of their secretion products into two groups. Neoplasms that produce and secrete (glyco)peptide hormones and biogenic amines comprise the first group. The second group
Università Cattolica del Sacro Cuore, Rome, Italy
ENETS Center of Excellence, Neuroendocrine Tumour (NET) Center, Rome, Italy
Search for other papers by Guido Rindi in
Google Scholar
PubMed
ENETS Center of Excellence, Neuroendocrine Tumour (NET) Center, Rome, Italy
Search for other papers by Frediano Inzani in
Google Scholar
PubMed
types or, perhaps, neuroendocrine-committed cells do transform, generating neoplasms. Neoplasms made by cells with a neuroendocrine phenotype are today defined as neuroendocrine neoplasia (NEN). Similar to neuroendocrine cells, NEN are observed in pure
Search for other papers by Yulong Li in
Google Scholar
PubMed
Search for other papers by William F Simonds in
Google Scholar
PubMed
different treatment approaches. Being familiar with their unique features and natural history may facilitate diagnosis and help to establish individualized management to improve outcomes. We herein summarize and update the knowledge on endocrine neoplasms
Search for other papers by Fritz-Line Vélayoudom-Céphise in
Google Scholar
PubMed
Search for other papers by Pierre Duvillard in
Google Scholar
PubMed
Search for other papers by Lydia Foucan in
Google Scholar
PubMed
Search for other papers by Julien Hadoux in
Google Scholar
PubMed
Search for other papers by Cecile N Chougnet in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by David Malka in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Oncology, Pathology, Department of Biostatistics and Epidemiology, Departments of Gastroenterology, Thoracic Oncology, Digestive Surgery, Medical Imaging, Faculté de Médecine Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Search for other papers by Joël Guigay in
Google Scholar
PubMed
Search for other papers by Diane Goere in
Google Scholar
PubMed
Search for other papers by Thierry Debaere in
Google Scholar
PubMed
Search for other papers by Caroline Caramella in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Oncology, Pathology, Department of Biostatistics and Epidemiology, Departments of Gastroenterology, Thoracic Oncology, Digestive Surgery, Medical Imaging, Faculté de Médecine Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Search for other papers by David Planchard in
Google Scholar
PubMed
Search for other papers by Dominique Elias in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Oncology, Pathology, Department of Biostatistics and Epidemiology, Departments of Gastroenterology, Thoracic Oncology, Digestive Surgery, Medical Imaging, Faculté de Médecine Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Search for other papers by Michel Ducreux in
Google Scholar
PubMed
Search for other papers by Jean-Yves Scoazec in
Google Scholar
PubMed
Search for other papers by Eric Baudin in
Google Scholar
PubMed
Introduction Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are rare tumors defined by the expression of specific diagnostic biomarkers ( Baudin 2007 , Modlin et al . 2008 , Yao et al . 2008 ). Their prognosis is best characterized by
Department of Clinical Sciences, University of Bergen, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia
Search for other papers by Grace Kong in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
-term toxicity. 177 Lu-DOTA-octreotate (LuTathera) has recently obtained regulatory approval for patients with progressive metastatic grade 1–2 GEP NET. High-grade gastroenteropancreatic neuroendocrine neoplasms: NET G3 and NEC Gastroenteropancreatic
Search for other papers by Pedro Weslley Rosario in
Google Scholar
PubMed
Search for other papers by Gabriela Franco Mourão in
Google Scholar
PubMed
Search for other papers by Maurício Buzelin Nunes in
Google Scholar
PubMed
Search for other papers by Marcelo Saldanha Nunes in
Google Scholar
PubMed
Search for other papers by Maria Regina Calsolari in
Google Scholar
PubMed
Introduction Recently, it was proposed that some papillary thyroid carcinomas (PTC) will no longer be termed ‘cancer’ and instead be called ‘noninvasive follicular thyroid neoplasm with papillary-like nuclear features’ (NIFTP) ( Nikiforov et
NHS Nightingale Hospital London, London, UK
Search for other papers by Ashley K Clift in
Google Scholar
PubMed
Search for other papers by Andrea Frilling in
Google Scholar
PubMed
Introduction Neuroendocrine neoplasms (NEN) represent a heterogeneous class of tumours that arise from nigh ubiquitously dispersed neuroendocrine cells, which may be stratified into clinically meaningful sub-groups on the basis of their
LuGenIum Consortium for Independent Research, Milan, Rotterdam, Bad Berka, London
Search for other papers by Lisa Bodei in
Google Scholar
PubMed
Emeritus Professor Gastroenterological Surgery, Yale University, School of Medicine, New Haven, Connecticut, USA
Search for other papers by Irvin M Modlin in
Google Scholar
PubMed
Search for other papers by Markus Luster in
Google Scholar
PubMed
Search for other papers by Flavio Forrer in
Google Scholar
PubMed
Search for other papers by Marta Cremonesi in
Google Scholar
PubMed
Search for other papers by Rodney J Hicks in
Google Scholar
PubMed
Search for other papers by Samer Ezziddin in
Google Scholar
PubMed
Search for other papers by Mark Kidd in
Google Scholar
PubMed
Search for other papers by Arturo Chiti in
Google Scholar
PubMed
therapy-related myeloid neoplasms (t-MNs) 30–70months after PRRT at the Erasmus Medical Center (EMC) Rotterdam. Compared to the rest of the cohort who also received PRRT, these 20 patients had more cycles of chemotherapy, more cycles of alkylating agents
Maimonides Institute for Biomedical Research of Cordoba (IMIBIC); Reina Sofia University Hospital, Córdoba, Spain
Search for other papers by Aura D Herrera-Martínez in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
Search for other papers by María A Gálvez Moreno in
Google Scholar
PubMed
Search for other papers by Justo P Castaño in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Introduction Neuroendocrine neoplasms (NENs) represent a heterogeneous group of rare neoplasms, which originate from enterochromaffin cells that are located throughout the whole body. NENs located in the gastrointestinal tract and pancreas are